Financials
Financial year 2025
Revenue
€ 675.3 million
▲ 8% vs 2024
Profit
Growing€ 30.9 million
▲ 106% vs 2024
Debts
Low€ 76.2 million
▼ 27% vs 2024
Janssen-Cilag from Beerse, company number BE0415283427, closed financial year 2025 with a result of € 30.9 million after tax. For that financial year Janssen-Cilag recorded revenue of € 675.3 million and equity of € 101.3 million. Compared with financial year 2024, the result moved from € 15 million to € 30.9 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
What happened at Janssen-Cilag?
What happened at Janssen-Cilag in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Nicoleta - Roxana Botea stepped down as director. NBB
- Luc van Oevelen stepped down as director. NBB
- Marleen Hoebus stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 30.9 million (▲ 106% vs 2024). Source: NBB ↗
- Nicoleta - Roxana Botea became a director. NBB
- Luc van Oevelen became a director. NBB
- Marleen Hoebus became a director. NBB
- New establishment in Machelen (Brab.). KBO
In short
From € 20.2 million profit in 2021 to € 30.9 million profit in 2025.
Paid € 34.8 million in corporate taxes since 2021.
Best year ever: 2025, with € 30.9 million profit.
Paid out € 45 million in dividends to the owners in total.
A new publication or filing at Janssen-Cilag? We notify you, reason included.
Follow Janssen-CilagNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Janssen Pharmaceutica NV (100%) and Johnson & Johnson International (0%).
Directors
According to the 2025 annual accounts
Marleen Hoebus
Managing director
since 2021 · until 2027
Nicoleta - Roxana Botea
Managing director
since 2024 · until 2030
Luc van Oevelen
Managing director
since 2024 · until 2030
Shareholders
Johnson & Johnson International
0%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Antwerpseweg 15-17
2340 Beerse
Leonardo da Vincilaan 15
1831 Machelen (Brab.)
Active since 6 August 2012
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0415.283.427
- VAT number
- BE 0415.283.427
- Registered office
- Antwerpseweg 15-17, 2340 Beerse
- Names & denominations
- Johnson & Johnson, J&J, Johnson & Johnson Innovative Medicine, J&J Innovative Medicine · Janssen-Cilag
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 August 1975
- Peppol
- Active · Active since 23 Mar 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten